08:08 AM EDT, 06/25/2025 (MT Newswires) -- Hims & Hers Health ( HIMS ) will continue offering low-cost weight-loss injections despite Novo Nordisk's ( NVO ) decision to terminate their distribution partnership, Bloomberg reported Tuesday, citing CEO Andrew Dudum.

"We're upset that Novo is feeling the pressure and not comfortable," Dudum said but "there's just no way in hell we're going to cave on that," he added.

Novo ended the partnership Monday with Hims, citing "deceptive marketing" related to compounded versions of its weight-loss drug Wegovy.

"The big issue with Hims is that we had an agreement that the mass compounding would stop and unfortunately it didn't stop," said Ludovic Helfgott, executive vice president of product and portfolio strategy at Novo.

Hims and Novo did not immediately respond to requests for comment from MT Newswires.